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We have investigated Th cell  recognition of the 
HIV core protein p24 by using CD4' T cell clones 
derived  from  cynomolgus  macaques  immunized 
with  hybrid HIV p24:Ty virus-like particles (VLP). T 
cell lines from  two  immunized animals responded 
to p24:Ty-VLP, control Ty-VLP, purified p24, and 
whole inactivated HIV, indicating the presence of T 
cells specific  for  p24 as well as  the Ty carrier pro- 
tein. The HIV determinants recognized by the T cell 
lines were  identified by using a series of overlapping 
peptides synthesized according to  the sequence of 
p24.  Both T cell lines recognized  peptide 11 (amino 
acids 235-249) and peptide 14 (amino acids 265- 
279). In addition, one T cell line also responded to 
peptide 9 (amino acids 215-229).  Definitive identi- 
fication of two T cell epitopes on p24  was  confirmed 
at  the clonal level:  from a total of four T cell clones 
generated from one of the T cell lines, two  respond 
specifically to peptide 11 and two to peptide  14.  The 
T cell clones were CD4' and MHC class 11-restricted 
and secreted IL-2 in response to stimulation with 
purified  p24, inactivated HIV or a single synthetic 
peptide.  The  specificity of the Th clones for variant 
peptides demonstrated cross-reactivity with two 
simian immunodeficiency virus isolates, but only 
limited responses to HIV-2 sequences. However, the 
Th cell epitopes identified on p24 are highly  con- 
served  between 12 HIV-1 isolates and were  recog- 
nized by both of the immunized primates. These 
sequences may therefore be useful for priming a 
broadly reactive immune response to HIV-1. 
The ability  to  induce HIV-specific Th cells is likely  to 
be a n  essential requirement of any candidate vaccine 
designed  to  prevent  or  control HIV infection.  Th  cells  are 
a vital  component of the  immune  system  and  are required 
for  both  antibody  and cytotoxic responses [ 1-3). In  addi- 
tion,  evidence of protective  immunity has  been reported 
for other viral infections by the generation of Th cell 
populations  directed  against  viral core antigens  (4-7). 
Previous reports have indicated that the Th cell re- 
sponse  to HIV proteins is weak  or  undetectable  in HIV- 
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infected  individuals  especially  in the  late stages of dis- 
ease  (8-10). In contrast,  consistent  proliferative re- 
sponses  against HIV proteins,  including  p24,  are  detected 
in HIV-infected non-human  primates  (1  1, 2). These  an- 
imals,  unlike  humans,  have so far failed  to  develop HIV- 
related  disease  symptoms.  Furthermore,  in HIV seropos- 
itive humans, a reduction  in  anti-p24  antibody levels has 
been  shown  to  correlate  with  the  onset of disease pro- 
gression (13,  14).  The  p24  protein  is  therefore  worthy of 
consideration for inclusion in a combination vaccine 
against HIV. 
We have  shown previously that a protein, p l ,  encoded 
by the  yeast  retrotransposon Ty can be used as a  self- 
assembling,  particulate  carrier  for  recombinant Ag (1 5- 
17). Ty is a repetitive, mobile DNA element  that moves 
from  one  genomic location to  another via a n  RNA inter- 
mediate. The RNA is  packaged  into VLP3 by  Ty-encoded 
proteins (Ty-VLP) (18,  19). 
The  structural  components of the Ty-VLP are encoded 
by the Ty gene, TYA (19). If the TYA gene alone is 
expressed  to  produce  protein pl ,   th is  will assemble  into 
particles even in the absence of the other Ty-encoded 
proteins [ 19).  The  insertion of additional  protein  coding 
sequences at   the 3' end of the TYA gene  results  in  the 
production of pl-fusion  proteins  that  retain  the  ability  to 
self-assemble [ 15, 17). This system provides a useful 
means of presenting antigens in a polyvalent form as 
hybrid Ty-VLP. The hybrid VLPs are 50 to 80 nm in 
diameter,  contain  approximately  300  copies of the fusion 
protein, and  have been  used  to elicit the production of 
antibodies  against  the  non-Ty  components [ 15,  17). 
In this report we demonstrate the induction of HIV- 
specific CD4+ Th cells in cynomolgus macaques by im- 
munization  with HIV p24:Ty-VLP. MHC class 11-restricted 
T cell clones have been derived from the immunized 
animals  and used  to  delineate  two  Th  epitopes  in highly 
conserved  regions of the HIV core  protein  p24. 
MATERIALS AND METHODS 
Ag. HIV p24:Ty VLP containing  HIVgag  codons  104-308 of isolate 
yeast as described  previously  (1 7). The HIV p24:Ty Ag. purified  from 
IIIB (20)  were  constructed by expressing a TYA:p24 fusion  gene  in 
yeast  extracts  on a 15  to  45%  sucrose  gradient,  were  electrophoresed 
on 9% SDS polyacrylamide  gels and  stained  with Coornassie brilliant 
assay obtained from Bio-Rad Laboratories.  Purified p24:Ty-VLP 
blue (1 9). The  protein  concentrations  were  determined by a Bradford 
were prepared for electron microscopy and stained with uranyl 
acetate as previously  described (1 8). Nonparticulate  p24  was  cleaved 
and purified  from  hybrid HIV p24:Ty-VLP modified to  incorporate 
Abbreviations used in this paper: VLP. virus-like  particles: SIV. sim- 
ian immunodeficiency virus. 
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1678 Th CELL DETERMINANTS ON HIV p24 
the recognition site  for  the blood coagulation factor Xa between the 
Ty and  p24 polypeptide sequences  (2 1). The  purity of the  p24 prep- 
aration  was  greater  than 90% (21). HIV-1 (RF) was grown  in H9 cells 
and high titer supernatants (10' TCID,/ml) were inactivated by 
heating a t  60°C for  1  h.  Overlapping synthetic peptides  correspond- 
ing to gag  p 17  and  p24  sequence of  HIV- 1 (ARV-2/SF2) (22.23) were 
manufactured for the MRC  AIDS Directed Programme by Cambridge 
C- or N-terminal cysteine added to  facilitate chemical  coupling for 
Research Biochemicals. Each peptide was  15  residues long with a 
use  in  studies  unrelated  to  those described here.  Substituted  ana- 
logues of two of the HIV-1 peptides (pl l and  p14) were synthesized 
according to  the  sequences of the corresponding  regions of HIV-2 
and two SIV isolates from macaques (22). The HIV-2 ROD, SIV- 
M 142.  and SIV-M25 1  peptides from  the  corresponding region of the 
HIV-1 peptide 14 and the equivalent HIV-1 peptide. without the 
added  C-terminal cysteine  (amino  acids 265-279).  were synthesized 
by Jonathan Rothbard (ICRF. London). The HIV-2 and SIV peptides 
275 to prevent cross  linking of the peptides. The HIV-2/SIV-M142 
have a Ser  substituted for the Cys in the  natural  sequence  at position 
and SIV"251 peptides from the corresponding region of  HIV-1 
peptide  1  1 (amino acid  235-249)  were synthesized  for  the MRC  AIDS 
Directed Programme by Peptide and Programme  Research  Consult- 
ants, Reading. UK. The sequence of the synthetic peptides was 
confirmed by amino acid analysis and each peptide had a single 
major peak on HPLC. Peptides  were dissolved in RPMI- 1640 medium 
supplemented with M 2-ME and stored a t  -70°C until required 
for  use. 
T cell clones. Proliferative CD4+ T cell lines and clones were 
generated from PBMC  of two  cynomolgus macaques (Macacafascl- 
cularls) immunized with 50 pg of p24:Ty-VLP absorbed  onto  alum. 
Animals received three 1-ml i.m. injections of the Ag preparation a t  
6-wk intervals. PBMC were  purified by centrifugation on a percoll 
gradient from whole blood samples.  taken  either  four  weeks  after 
the  1st boost (monkey H69) or two weeks  after  the  2nd boost (monkey 
H70). Cells were cultured a t  1 x 1O6/ml in RPMI-1640 medium 
supplemented with 10% FCS in the presence of antigen (p24:Ty- 
VLPs. 1  pglml) a t  37°C in a C02  incubator. T cell lines were estab- 
lished by re-stimulation of the  cultured T  cells a t  1 x 1OS/ml every 
14  days with antigen  and autologous  feeder  cells  (irradiated PBMC 
at  5 x 105/ml). Fresh medium and IL-2 (human rIL-2. 5 U/ml) were 
added 5 days  after Ag stimulation. T cell clones  were established 
from T cell line 70.24 by limiting dilution a t  1 cell/well in 200 pl 
volumes  in 96 well tissue  culture  dishes in the  presence of autologous 
feeder cells. p24:Ty-VLP (2 pglml) and IL-2 (10 U/ml). A further  25 
pl of medium containing 50 U/ml IL-2 was added 5 days later.  After 
14  days clones  were restimulated with Ag and IL-2 and expanded in 
24-we11 plates. 
Prollferatlon assay. Rested T cells (14 days after the last Ag 
stimulation) were cultured at  1 X 105/ml in  100 or 200 pl volumes 
ogous APC (5 X 105/ml PBMC or 1 x 105/ml EBV-transformed B 
in 96 well flat-bottomed plates wiht antigen  and  irradiated  autol- 
cells). Unless otherwise indicated the  concentrations of Ag used  were 
5 pglml of p24:Ty-VLP or control Ty:VLP. 1 pglml of purified p24 or 
synthetic peptide. and  1/10 to 1/100 dilution of HIV-infected H 9  cell 
supernatant.  Cultures were incubated for  2 or 3 days  and pulsed for 
the  last 4  h  with 0.5 pCi  of (3H]thymidine. Results  are given as mean 
cpm of [3H]thymidine  incorporation after  harvestingand scintillation 
counting of triplicate cultures. 
IL-2 assay. IL-2-release was assessed by testing the ability of 
eration of the IL-2-dependent CTLL-2 cell line. Supernatants (50 PI)  
supernatants, removed after  24 h of culture,  to  support  the prolif- 
were  added to 50 pl (1 x 1 04) CTLL-2 cells that were washed  free of 
1L-2 for 2 h before the  assay. CTLL proliferation was determined 
after  24 h by [3H]thymidine  incorporation. Results  are  mean  values 
for triplicate assays given as IU of  IL-2. determined by comparison 
with a standard  curve of  CTLL proliferation  with dilutions of human 
rIL-2. 
MHC restrtctlon and phenotyplc  analysts. The MHC restriction 
of the T cell lines on clones  was examined by testing  their prolifer- 
ative  response  against p24:Ty VLP (1 pglml) and autologous APC in 
the  presence of mAb specific  for human MHC molecules. Antibodies 
were  added to  cultures a t  a final  concentration of 1/200  and  1/1000 
dilution of ascites fluid and proliferation was  assayed two days  later 
as described above. Antibody L203. specific for nonpolymorphic 
determinants of human MHC class II  molecules (HLA-DR). was ob- 
Culture Collection (Rockville. MD). Antibody W6/32 is specific for a 
tained from hybridoma cells purchased from the American Type 
monomorphic determinant  on  human MHC class I molecule (HLA-A, 
-B. and -C). Each of the anti-human reagents cross-reacted with 
monkey cells: typical values for macaque PBMC were 10  and 95% 
positive cells  with L203  and W6/32.  respectively. Surface  marker 
analysis  was performed by labeling the T  cells  with the  anti-human 
mAb T1 1, 4B4 (Coulter). OKT4 (Ortho). Leu-2a (Becton Dickinson). 
specific for CD2. CDw29. CD4. and CD8 determinants. respectively. 
Results  are expressed as the percentage of positive cells on flow 
microfluorimetry analysis  after  subtraction of background staining 
with a mouse IgG control. 
RESULTS 
Characterization of the HIV p24:Ty-VLP. The  partic- 
ulate  nature of the HIV p24:Ty Ag was demonstrated by 
electron microscopy (Fig. 1). The particles  have  a diame- 
ter of approximately 80 nm.  The  purity of the Ag prepa- 
ration was determined by SDS-PAGE. Examination of 
Coomassie-stained gels indicated that greater than 90% 
of the material  migrates as a 70-kDa protein (data not 
shown).  The  presence of p24 Ag was confirmed by im- 
munoblotting and immunogold electron microscopy (1 7). 
Induction of HIV-specific T cell immunity and the 
generation of p24-specific  T cell clones. PBMC isolated 
from cynomolgus macaques immunized with 50 pg of 
p24:Ty-VLP as   an  alum  precipitate, were able to prolif- 
erate  and incorporate [3H]thymidine in  response  to  stim- 
ulation  with purified p24:Ty-VLP. Significant  T cell re- 
sponses to  p24 were detected 2 wk after  the  first immu- 
nization and for up to 8 wk after  the  third immunization. 
Furthermore,  anti-p24  antibodies, as well as  proliferative 
T cell responses, were detected in a total of eight animals 
after immunizations  with 50 or 500 pg of p24:Ty-VLP 
with  or  without  alum as adjuvant  (24).  T cell lines were 
established from the two animals  that  had been immu- 
nized with 50 pg p24:Ty-VLP. and maintained by re- 
peated Ag stimulation  in vitro for a t  least 6 mo. The T 
cell lines 69.24 and 70.24 proliferated in response to 
p24:Ty-VLP. control Ty-VLP, purified p24. and to whole, 
inactivated HIV (Table I). This specificity pattern indi- 
cated that  the cell line  contained  T cells directed against 
both the Ty carrier protein and HIV p24. T cell clones 
were generated from line  70.24 by limiting dilution. A 
total of four  clones were successfully  maintained  in  cul- 
ture  and  each of these  was specific for HIV p24 (Table I). 
Identification of Th cell epitopes on p24. The HIV 
determinants recognized  by the T cell lines were identi- 
%le;. . > 
Flgure 1 .  Electron  micrograph of purified HIV p24:Ty-VLP. The par- 
ticles were stained with uranyl acetate. 
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TABLE I 
1679 
Identlflcatfon of determinants on HIV-024 recoanized bu macaaue CD4* T cell lines and clones 
Prollferative Response  (cpm) to 
T Cell Whole 
Medlum p24:Ty-VLP p24 Ty-VLP  HIV-1 
Synthetic peptldes 
P9 P I 1  ~ 1 4   ~ 1 6  
RF 1215-229In 1235-2491 1265-2791 1285-2991 
Expt. 2 4,449 25.578 
Expt. 3' 1.360 ND 
69.24 
Expt. l b  
Expt. 2 4,496 19,405  18,558  12.224 ND 20,452 15,096 1 6 . 9 5 5  
808 2.459  2.728  1,626 ND 3,544  2 150,636  864
ND 
Expt. 3' 4,144 ND  ND ND 12,573 ND  ND ND ND
Clone ~~ ~~ 
70.24.29  580  14,310 3,694 788 ND ND 3.670  182 ND 
70.24.45 1,101 14,382 6.938 946 ND  ND 164  13,456 ND 
440 5,503 2.099 392 ND 70.24.51 ND 252 4.620 ND 
70.24.53 
Expt. 1 128 9.843 8,073 216 ND ND - 10,101 218 ND 
Exut. 2d 41 1 ND ND ND 4,709 ND ND ND ND 
"Amino  acids of Corresponding HIV-lsF2 gag sequence (22). 
Response  values considered to be positive are underlined. 
Experiment was performed with EBV-B cells as APC. 
Experiment was performed by using different culture and  harvesting  facilities in a containment 3 laboratory. 
fied by testing  their specificity with 20 overlapping 15 
amino acid-long synthetic  peptides  representing  the  en- 
tire  sequence of the gag component  present  in the hybrid 
VLP (17 for p24 and 3 for  p17).  The proliferative T cell 
responses  to  four of the  p24 peptides is shown  in  Table 
I. The  remaining  peptides gave responses  essentially  sim- 
ilar to that  shown for peptide 16. Lines 69.24  and  70.24 
both responded to peptide 11 (amino  acids  235-249) and 
to peptide 14 (265-279). In addition, line 69.24 also 
recognized peptide 9 (215-229). 
T cell clones  generated from line  70.24 were used to 
definitively identify Th epitopes on HIV p24 at  the clonal 
level. From a  total of four clones examined, clones 
70.24.29  and  70.24.53 responded specifically to peptide 
11  and clones 70.24.45  and  70.24.51 responded specifi- 
cally to peptide 14 (Table I and Fig. 2).  Each of the clones 
proliferate and secrete IL-2 in  response to Ty:p24-VLP 
and purified p24, and a  single  synthetic peptide but  not 
on  stimulation  with  control Ty particles.  These recogni- 
tion patterns indicate that the T cell clones are HIV- 
specific. Further confirmation  was  obtained by the  stim- 
ulation observed of clone 70.24.53  with  inactivated HIV 
(Table I). 
Eflect of sequence  variation  between  HIV-I,  HIV-2, 
and SIV on  T-cell  recognition. The regions of HIV p24 
spanned by peptides 1 1 and 14 are highly conserved 
between 12 HIV-1 isolates (HXB2, BH102, BH5, PV22, 
BRU, MN, SF2, CDC41, WMJ21, RF, MAL, ELI) (22). 
However, there  are a number of sequence  changes  in the 
corresponding regions of  HIV-2 and SIV (Fig. 3). We there- 
fore investigated the proliferative responses of the T cell 
clones to equivalent HIV-2  ROD,  SIV-M142 and SIV- 
M251 peptides. The  responses of two of the clones 
against these peptides are shown in Figure 3. Clone 
70.24.45 (which recognizes HIV-1 gag peptide 14) did not 
give a  significant proliferative response  to the equivalent 
HIV-2 peptide. However, cross-reactivity  was  demon- 
strated  with  the two SIV peptides. It is possible that  the 
Ile to Ser  change at position 275,  rather  than  the Ile to 
Cys in the  natural  sequences, could account  for reduced 
activity of these peptides. However, this is unlikely since 
a comparison of the HIV-1, HIV-2, and SIV sequences 
with  reference  to the proliferation observed indicates that 
the recognition of the epitope is most affected by amino 
acid substitutions at residues  270 and 271 (Fig. 3). Amino 
acid substitutions  corresponding  to natural variation be- 
tween HIV- l and HIV-2/SIV were also  found to be critical 
for T cell recognition of peptide 11. The HIV-2 and SIV- 
M25 1  sequences in this region are identical  to  each  other 
and differ from HIV-1 peptide 11 by changes at residues 
245  and  246. Clone 70.24.53 gave only a weak response 
with its equivalent HIV-2/SIV-M142 peptide, and recog- 
nition  was completely abrogated by a further  substitution 
at residue  244 as seen in the SIV"251 peptide (Fig. 3). 
The addition of C-terminal Cys residues to the HIV-1 
peptides (for use  in  unrelated  studies) may have  resulted 
in  dimer  formation, however, this does not appear to have 
affected their activity. The response curves of clone 
70.24.45 to peptide 14, synthesized with or without the 
additional Cys were essentially identical (in  one experi- 
ment  the  peak  responses at 1 .O pg/ml were 16.401 and 
15,957 cpm, respectively). Furthermore, the synthetic 
peptides with the added Cys residues  had  similar T-cell 
stimulatory  capacity as the  full  length  recombinant  p24 
(Fig. 2). 
MHC restriction  and  phenotype of the T cell lines  and 
clones. An analysis of the  surface  markers  present on 
the T cell lines and clones with mAb demonstrated that 
they were CD2+, CD4+, CDw29'. and CD8- (Fig. 4).  The 
effects of mAb specific for human MHC molecules on 
antigen-induced proliferative responses suggested that 
the T cell recognition was MHC class 11-restricted. Anti- 
body L203, specific for human HLA-DR inhibited the 
proliferative response of line  70.24  and clone 70.24.53 
(Fig. 4). At a 1/100 dilution of L203  ascites,  the  response 
of line 70.24  and of clone 70.24.53  was reduced by 65 to 
70%  (after  subtraction of backgrounds,  responses were 
reduced from 8125 to 2500 cpm and 13,250 to 4,625 
cpm, respectively). In contrast,  the addition of mAb W6/ 
32, specific for a monomorphic determinant on human 
MHC class I molecules (HLA-A, -B, and -C), did not  signif- 
icantly affect the T cell responses (Fig. 4). The net 
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1680 Th CELL  DETERMINANTS ON HIV p24 
by HIV p24 specific T cell clones. T cell 
FLgure 2. Proliferation and IL-2-release 
clones  70.24.45 (a and c)  and  70.24.53 (b 
and d )  were tested  for  antigen  specificity 
against a range of doses of p24:Ty-VLP. 
purified p24.  control Ty-VLP and  synthetic 
peptides. The response curves of clone 
70.24.45 are shown with peptides p10 
(amino  acids  225-239).  p  1 1 (235-249)  and 
p12  (245-269)  and T-cell clone  70.24.53 
with peptides p13 (255-269). p14 (265- 
erative responses [a and b) are shown 
279)  and  p15  (275-289).  Results of prolif- 
above the corresponding curves for IL-2 
release (c  and d )  tested  in  the  same  exper- 
iment. 
T cell clones for synthetic peptides corre- 
FLgure 3. Specificity of HIV p24-specific 
c3 CLONE 70.24.53 
12'ooo J PZ~:TY-VLPS 
6,0001 x 
4 , 0 0 0  1 
2.000 
0- 0 0.03 0 . 1  0.3 1 3 
5 ,@ 
@ CLONE 70.24.45 
4°.000 1 P24:Ty-VLPs 
t
30,000 
P 2 4  
-4" I Ty-VLPs/P(3/P15 /"- ;;;I p 
1 0 
10 0 0.03 0.1 0.3 1 3 10 
4,  @ 
O L  1 
0 0.03 0 . 1  0.3 1 3 10 
Antigen Concentration (ug/ml) 
C L O N E  70.24.53 CLONE 70.24.45 
f G S D I A C T T S T L O E Q I ( C )  (HIV-1) t K R W I I L G L N K I V R M Y ( C )  (HIV-1) 
t - - - - - - - - - - v E - _ _  (HIV-2/SIV-M142) R - - - Q  I - - Q - S  - - - - (HIV-2) 
t - ---- "" v D - - -  (SIV-M251) - R " - Q - R  - Q " j  _ _ _ -  (SIV"251) - R " - 0 -  - - Q - S - - - -  (SIV-Ml42)  
sponding  to  the  natural  sequences of  HIV- 1, 
HIV-2 and SIV. Results  are  proliferative  re- 2 - 1 0 , 0 0 0  
against  peptides  corresponding  to HIVl p24 - sponses  for clones  70.24.53  and  70.24.45 0 
residues  235-249  and  265-279,  respec- t= 8,000 
tively, and  against  peptides  synthesized  ac- 
cording to the equivalent  regions of HIV-2, 
SIV-M142, and SIV-M251. The HIV-2 and 
SIV peptides  from the corresponding  regions 
P 6,000 
of HIV-1 residues  265-279  have  a  Ser  sub- 
stituted  for  a Cys in  the  natural  sequence a t  
position 275.  Sequence of peptides  is given w r 4,000 
in  standard  single  letter code. 
.- + 
P 
0, 
- 
.- 
a 
E 2 2,000 
c 
I 
30,000 
20,000 
1 0 , 0 0 0  h 
0 0.01 0 . 1  1 10 100 0 0.01 0.1 1 10 100 
Peptide Concentration (ug/ml) 
changes  in  the  responses observed with W6/32 (5 to 13%) primates immunized with hybrid HIV p24:Ty-VLP. The 
were within  the experimental  error of the cpm obtained 
in  the  absence of added antibody.  The inability of APC 
from monkey H69 to present antigen to T cells from 
monkey H70 is also  shown  in Figure 4. T cell line 70.24 
failed to respond to p24:Ty-VLP in  the presence of irra- 
diated PBMC from monkey H69. This confirms the MHC 
restriction of the response and suggests that monkeys 
H69 and H70 are incompatible at  the DR locus. 
DISCUSSION 
This  report  describes the generation and  fine specific- 
ity of HIV-specific CD4+ T cell clones generated from 
determinants recognized  by the MHC class 11-restricted T 
cell clones were mapped to conserved regions of the 
HIV-1 p24 protein. However, our  results  indicate that T 
cell recognition of the gag protein is affected by amino 
acid sequence  variation between HIV- 1 and HIV-2 or SIV. 
Previous studies  on  the mapping of Th epitopes on HIV 
proteins  have focused on envelope Ag (25-29). However, 
despite the presence of these epitopes, in addition to CTL 
epitopes (30, 31)  and B cell epitopes that elicit neutraliz- 
ing antibodies  (32-35).  attempts to protect non-human 
primates with envelope-based preparations has so far 
been unsuccessful (36, 37). There are several lines of 
evidence that suggest that a vaccine against HIV that 
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type of T cell lines and clones. Results of 
FLgure4. MHC restriction and pheno- 
MHC restriction analysis are shown as cpm 
for proliferative responses of T cells with 
autologous APC alone (no Ag) or against 
p24:Ty-VLP (p24) in the presence 1/1000 
(left-hand column) or 1/100 (right-hand 
column) dilution of mAb ascites specific for 
human MHC class I1 (L203) or class I (W6/ 
of line 70.24 to p24 in the presence of 
32) molecules. Also shown as the response 
allogenic (monkey 69) APC. 
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includes all or part of the p24  protein  in an immunogenic 
form, may have greater potential to confer protection 
than those based on envelope alone. In studies of influ- 
enza (7, 38) and hepatitis B (4-6) viruses, vaccination 
with core antigens has been  shown to prime Th cells that 
cooperate with B cells in the production of neutralizing 
antienvelope Ab, which are  at least  partially protective 
against live virus challenge. Furthermore. in HIV sero- 
positive patients both T cell proliferative responses  and 
antibody levels against  p24 decline with the progression 
of HIV-related disease (9, 10,  13,  14). However, reported 
attempts to induce HIV p24 specific Th responses in 
immunized animals  have  been largely unsuccessful (9, 
39). Proliferative lymphocyte responses  to  p24 were not 
detected in PBMC from chimpanzees after inoculation 
with  vaccinia  virus HIV p24  recombinants (39). Further- 
more in  a  study of cynomolgus macaques immunized with 
a recombinant gag  protein purified from Escherichia 
coli, at least  six  injections  in IFA were required to induce 
a  detectable proliferative response  to  p24 (9,  40). In con- 
trast, significant  T cell proliferation was  demonstrated 
in PBMC from cynomolgus macaques  after only one or 
two immunizations  with hybrid HIV p24:Ty-VLP with or 
without  alum as adjuvant  (24,  and  this  study). Specificity 
analysis of T cell lines  and clones  generated from two of 
the immunized animals demonstrated the induction of 
MHC class 11-restricted T cells specific for HIV sequences. 
The T cells were CD4+ CDw29' and secreted IL-2 on 
antigen  stimulation and therefore probably belong to the 
helper-inducer subpopulation. These data suggest that 
immunization  with  a  recombinant g a g  protein, incorpo- 
rated into a hybrid polyvalent particle containing 300 
copies of the Ag, is an effective method for the  generating 
HIV p24-specific memory T cells in  primates. 
Fine specificity analysis of T cells from the immunized 
macaques  against  a  panel of overlapping synthetic pep- 
tides,  corresponding to the sequence gag  protein,  resulted 
in  the delineation of three new Th epitopes on p24. Two 
of the  determinants were recognized by T cell lines  from 
two animals and definitive identification of these epi- 
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topes was confirmed at  the clonal level: T cell clones 
derived from one of the T cell lines showed specific 
recognition of peptide 11 (235-249) or peptide 14 (265- 
279). Interestingly peptide 14 has also been shown to 
contain an epitope for CTL from HIV seropositive humans 
(41)  and includes the sequence Lys-Ile-Val-Arg (residues 
274-277)  which  corresponds to a  consensus motif sug- 
gested by Rothbard (42) as being common to a majority 
of T cell determinants. 
The  successful  generation of T cell clones specific for 
distinct determinants on HIV p24, has allowed us to 
examine the effect of sequence  variation between HIV- 1, 
HIV-2, and SIV on T cell recognition at  the epitope level. 
The region of HIV p24 spanned by p l l  is completely 
conserved between 12 HIV- 1 variants,  whereas peptide 
14 corresponds to a region with a single conservative 
amino acid substitution (Leu to Val) in one Zairian isolate, 
HIV-l.., (22). However, there is a  greater degree of vari- 
ability seen  when the  sequences  are compared with the 
corresponding regions of HIV-2 and SIV (22).  The  T cell 
clones, when  tested  against  analogues of peptide 11  and 
peptide 14, with  substitutions at sites corresponding to 
those  found  in the  natural sequences of  HIV-2  ROD, SIV- 
M142, and SIV-M25 1, showed significant  cross-reactiv- 
ity with SIV sequences  but limited recognition of the HIV- 
2 peptides. An examination of the sequence  changes in 
the HIV-2 and SIV peptides with reference to their ability 
to stimulate the T cell clones, reveals that Leu27o and 
Gly271 are critical for recognition of peptide 14. One or 
more of the amino acid subsitutions at position 265.  269, 
273, or 275 also  appeared  to affect T cell recognition, but 
to a lesser extent, as judged from the relatively small 
reduction in  the response of clone 70.24.45 to the SIV- 
M142 peptide compared with the HIV-1 peptide. It is 
possible that  this reduction in activity may have resulted 
from the substitution of Ser (rather than Cys, as in 
the  natural sequences) for the Ile at position 275 in the 
HIV-2 and SIV peptides. Substitutions at Leu245 and 
Gln246r in the HIV-2 and SIV equivalents of the HIV-1 p24 
peptide 11, significantly reduce the response of clone 
 at M
aynooth U
niversity (N
atl U
niv of Ireland) on June 14, 2016
http://w
w
w
.jim
m
unol.org/
D
ow
nloaded from
 
1682 Th CELL  DE ERMINANTS  ON HIV p24 
70.24.53. A further  amino acid change at residue  244 in 
the SIV”251 peptide reduced the response to back- 
ground levels. Therefore, natural sequence  variation be- 
tween HIV- l and HIV-2 or SIV does affect  T cell recogni- 
tion of the  gag protein.  Substitution at critical  sites may 
affect the capacity of the peptide or processed Ag to 
associate with the MHC molecule and/or  its recognition 
by the TCR. 
In a recent  report on anti-gag mAb,  Niedrig et  al.  (43), 
showed that certain  antibodies were cross-reactive  with 
SIV or HIV-2, whereas others were specific for HIV-1 
sequences. In contrast,  many of the B cell epitopes iden- 
tified on the envelope protein,  including  a major neutral- 
izing antibody site,  map to hypervariable regions of the 
protein and consequently are often HIV- 1 strain specific 
(33, 35). Furthermore, in a study with gpl20 specific 
human CD4’ CTL clones, only limited cross-reactivity 
was  demonstrated  against  synthetic peptides and gp120 
molecules from different HIV-1 isolates (30). This sug- 
gests that T cell recognition, as well as antibody  binding, 
is drastically  affected by sequence  variation  in the enve- 
lope protein. However, the T cell epitopes on p24 defined 
here,  map  to highly conserved regions of HIV- 1,  and were 
recognized  by both of the immunized primates. As these 
animals  appear  to be MHC incompatible at  the  class I1 
locus, this suggests that  these  sequences may be effective 
in a broad range of haplotypes. 
It remains  to be defined which viral antigens or which 
arm of the  immune  response may be capable of generat- 
ing protective immunity to HIV. Th cells specific for 
cross-reactive determinants on the HIV-1 proteins may 
be important for the development of anamnastic antibody 
or CTL responses.  Therefore conserved sequences of the 
HIV-1 gag protein, that include Th cells epitopes, may be 
a useful component of a combination vaccine against 
HIV. 
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